Brenipatide
A Lilly investigational peptide candidate being studied in alcohol use disorder, mood disorders, and other craving-linked conditions.
Also referenced as: LY3537031
Also appears in: Hormone
This compound has a genuine development or study trail, but it is not an approved routine drug.
Primary lane: Other. Also surfaces under Hormone for browsing and discovery.
LY3537031
No FDA label signal · 16 trials · 0 PubMed results
Brenipatide has human trials registered, but none have reported controlled results yet. Most current claims about what it does in people rest on preclinical (lab or animal) work, not published human data.
Brenipatide has 16 name-matched clinical trials (highest phase: Phase 3) and 0 PubMed-indexed publications and is not FDA-approved. Human trials are registered but none have posted results yet.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What brenipatide is
Brenipatide is an investigational Lilly compound best known right now for its development in alcohol use disorder and related neurobehavioral conditions rather than obesity.
Why it matters
It is one of the clearest examples of peptide/incretin biology being pushed beyond weight loss and diabetes into craving, relapse, and mood-linked therapeutic areas.
Regulatory context
Brenipatide is not FDA approved. It remains a pipeline drug with active clinical development.
Practical reading note
Brenipatide is useful in the library because it broadens the conversation beyond “which peptide causes the most weight loss” and toward where the mechanism may be expanding next.